D. Rimoldi

Discipline

Histoire, Philosophie et Sociologie des sciences (2) Economies et finances (1)

Type de document

Articles (20) Recensions (1)

Co-auteur

Date

Source

Mot-clé

Melanoma (19) Cells (12) Patients (11) Human beings (11) Patients (11) Cancer (10) cancer (8) Cancer (8) Antigens (8) ligne (7) T cells (7) Expression (7) Cell lines (7) protéine (6) membrane (6) analyse (6) Tumors (6) Analysis (6) Genes (5) Vaccination (5) Peptides (5) Addition (5) Vaccination (5) Tumors (5) puits (4) spectacle (4) mutation (4) Development (4) Proteins (4) Lymphocyte transformation (4)

Documents écrit par D. Rimoldi (20) | parle de D. Rimoldi (0)

Genomic and transcriptomic landscape of conjunctival melanoma.
K. Cisarova et al.
Conjunctival Melanoma Targeted Therapy: MAPK and PI3K/mTOR Pathways Inhibition.
I. El Zaoui et al. (3 juin 2019)
Comprehensive Genetic Landscape of Uveal Melanoma by Whole-Genome Sequencing.
B. Royer-Bertrand et al. (3 nov. 2016)
A Well-Controlled Experimental System to Study Interactions of Cytotoxic T Lymphocytes with Tumor Cells.
N.J. Neubert et al.
UV light signature in conjunctival melanoma; not only skin should be protected from solar radiation.
C. Rivolta et al.
Compact solid-state CMOS single-photon detector array for in vivo NIR fluorescence lifetime oncology measurements.
H.A. Homulle et al. (2016)
Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8(+) and CD4(+) T-cell responses with multiple specificities including a novel DR7-restricted epitope.
P. Baumgaertner et al. (2016)
Vaccination with LAG-3Ig (IMP321) and peptides induces specific CD4 and CD8 T-cell responses in metastatic melanoma patients - report of a phase I/IIa clinical trial.
A. Legat et al. (2016)
Nanosensors for cancer detection.
F. Huber et al. (2015)
Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization.
L. Baitsch et al. (2012)
Network-guided analysis of genes with altered somatic copy number and gene expression reveals pathways commonly perturbed in metastatic melanoma.
A. Valsesia et al. (2011)
BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.
L. Derré et al. (2010)
Frequent MAGE mutations in human melanoma.
O.L. Caballero et al. (2010)
Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens.
P. Baumgaertner et al. (2006)
Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma.
G. Bricard et al. (2005)
Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells
F. Berard et al.
In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes.
D.E. Speiser et al. (1999)
Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues.
D. Valmori et al. (1999)
APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth.
M. Hahne et al. (1998)
Inhibition of death receptor signals by cellular FLIP.
M. Irmler et al. (1997)